• No results found

Title: Investigating remission and relapse in type 1 diabetes. Immune correlates of clinical outcome in beta-cell replacement therapies

N/A
N/A
Protected

Academic year: 2021

Share "Title: Investigating remission and relapse in type 1 diabetes. Immune correlates of clinical outcome in beta-cell replacement therapies "

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle http://hdl.handle.net/1887/47907 holds various files of this Leiden University dissertation.

Author: Torren, C.R. van der

Title: Investigating remission and relapse in type 1 diabetes. Immune correlates of clinical outcome in beta-cell replacement therapies

Issue Date: 2017-04-12

(2)

C.R. van der Torren

β

CD80/86

α B

Treg APC Th1

β β β CTL

CD28 CTLA4

TCR

α

HLA Antigeen

AutoAb

Eilandje van Langerhans Tn

β

Abatacept Teplizumab

Otelixizumab IL1 Anakinra

Diamyd DiaPep IL1R Rituximab

β

0.1 1 10 100 1000

Autoantibodies 0

25 50 75 100

PR A

50 100 150 200

10

5

10

4

10

3

0

10

5

10

4

10

3

0 10

2

Efficacy

Side effects

aHSC-Tx

Cyclosporine

Rituximab Otelixizumab II Teplizumab II

GAD65 HSP60 Orale Insulin

Abatacept MMF + Daclizumab

Teplizumab III

Tregs Anti-IL1β

Otelixizumab III Azathioprine

IL-2+Rapamycin MTX

ATG

Insulin Vaccine

Pancreas Tx Islet Tx insulin therapy

Complication resistant patients Complication

prone patients

Investiga ting Remission and Relapse in Type 1 Diabetes C.R. v an der Torren

Investigating Remission and Relapse in Type 1 Diabetes

Immune Correlates of Clinical Outcome

in Beta-Cell Replacement Therapies

Referenties

GERELATEERDE DOCUMENTEN

Type 1 diabetes can only be cured through beta-cells, which then require adequate immune protection. For most patients with type 1 diabetes, current intervention

Immune intervention trials towards a cure for type 1 diabetes De (om)Weg naar Genezing van Type 1 Diabetes 17 Chapter 3. Fate of Transplanted Islets,

Type 1 diabetes can only be cured through beta-cells, which then require adequate immune protection. For most patients with type 1 diabetes, current intervention

Het verdient overweging onderzoek naar immunotherapie ook bij kinderen uit te voeren, aangezien de helft van de nieuwe patiënten met diabetes mellitus type 1 jonger is

Immunohistological staining for donor HLA using a unique panel of human monoclonal HLA-specific alloantibodies was performed on liver cryosections after validation on

Cumulative acute rejection incidence stratified for no antibody induction therapy (black dotted line), daclizumab induction therapy (red filled line) and ATG

Shown are immunosuppression levels: tacrolimus trough level (green dots), MMF dosage (blue dotted line); Plasma C-peptide levels (black squares) and period of insulin use

However, the majority became positive for class I antibodies (72%) or class II antibodies (72%) in the Luminex assay; positivity was not correlated to a higher number of donors or